deltatrials
Completed PHASE2 INTERVENTIONAL 3-arm NCT03372057

A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) (PRIMO)

A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Sponsor: SecuraBio

Conditions Peripheral T-cell Lymphoma
Interventions Duvelisib
Updated 26 times since 2017 Last updated: Mar 5, 2025 Started: Feb 22, 2018 Primary completion: Dec 22, 2023 Completion: Dec 22, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Peripheral T-cell Lymphoma and is currently completed. SecuraBio leads this study, which shows 26 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Dec 2017 – ~Mar 2018 · 3 months · monthly snapshot~Mar 2018 – ~May 2018 · 2 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Nov 2018 · 4 months · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jul 2019 · 7 months · monthly snapshot~Jul 2019 – ~Nov 2019 · 4 months · monthly snapshot~Nov 2019 – ~Oct 2020 · 11 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Jun 2021 · 2 months · monthly snapshot~Jun 2021 – ~Oct 2021 · 4 months · monthly snapshot~Oct 2021 – ~Jan 2022 · 3 months · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~Jun 2022 · 4 months · monthly snapshot~Jun 2022 – ~Mar 2023 · 9 months · monthly snapshot~Mar 2023 – ~Nov 2023 · 8 months · monthly snapshot~Nov 2023 – ~Jan 2024 · 2 months · monthly snapshot~Jan 2024 – ~Feb 2024 · 31 days · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Mar 2025 · 6 months · monthly snapshot~Mar 2025 – ~Apr 2025 · 31 days · monthly snapshot~Apr 2025 – ~Sep 2025 · 5 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

26 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Apr 2025 — Sep 2025 [monthly]

    Completed PHASE2

  3. Mar 2025 — Apr 2025 [monthly]

    Completed PHASE2

  4. Sep 2024 — Mar 2025 [monthly]

    Completed PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

▶ Show 21 earlier versions

  1. Feb 2024 — Jul 2024 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  2. Jan 2024 — Feb 2024 [monthly]

    Active Not Recruiting PHASE2

  3. Nov 2023 — Jan 2024 [monthly]

    Active Not Recruiting PHASE2

  4. Mar 2023 — Nov 2023 [monthly]

    Active Not Recruiting PHASE2

  5. Jun 2022 — Mar 2023 [monthly]

    Active Not Recruiting PHASE2

  6. Feb 2022 — Jun 2022 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  7. Jan 2022 — Feb 2022 [monthly]

    Recruiting PHASE2

  8. Oct 2021 — Jan 2022 [monthly]

    Recruiting PHASE2

    Status: Active Not Recruiting → Recruiting

  9. Jun 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  10. Apr 2021 — Jun 2021 [monthly]

    Recruiting PHASE2

  11. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

  12. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  13. Nov 2019 — Oct 2020 [monthly]

    Recruiting PHASE2

  14. Jul 2019 — Nov 2019 [monthly]

    Recruiting PHASE2

  15. Dec 2018 — Jul 2019 [monthly]

    Recruiting PHASE2

  16. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE2

  17. Jul 2018 — Nov 2018 [monthly]

    Recruiting PHASE2

  18. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2

  19. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  20. Mar 2018 — May 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  21. Dec 2017 — Mar 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • SecuraBio
Data source: SecuraBio

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Baltimore, United States , Bergamo, Italy , Bologna, Italy , Boston, United States , Charlotte, United States , Chicago, United States , Columbia, United States , Dallas, United States , Dresden, Germany and 24 more locations